Greiner sets strategic course for further growth: Mediscan becomes independent division of Greiner Group
The sterilization service provider Greiner Mediscan is being established as an independent division directly under Greiner AG and will no longer be managed within Greiner Bio-One International GmbH. The focus is on scaling technological capabilities in order to meet the increasing demand for sterilization services. Bernhard Achleitner is taking over as CEO of Greiner Mediscan, bringing many years of management and strategy experience in the pharmaceutical and biotechnology industries.
Greiner Mediscan, previously a subsidiary of Greiner Bio-One International GmbH, is being placed directly under the umbrella of Greiner AG as an independent division. With this move, Greiner is laying the foundation to purposefully drive Greiner Mediscan’s strategic development and scaling, and to further expand its position as a reliable partner for international customers.
Greiner Mediscan is already one of Europe’s leading providers in the sterilization of medical products, the sterilization of food packaging, and the functional improvement of plastics and semiconductors using ionizing radiation. Following the recent expansion of the Kremsmünster site in 2024 and an investment of 22 million euros, capacity has been significantly increased. The Kremsmünster site is now one of the largest sterilization centers in Europe. Driven by rising global demand for sterilization services – fueled by regulatory requirements and the increasing need for sterile products in the medical, pharmaceutical, and food industries – Greiner Mediscan is ideally positioned to participate in this growth thanks to its technological know-how.
“By positioning Greiner Mediscan as an independent division of the Greiner Group, we are creat-ing the conditions to leverage our innovative power and know-how even more broadly effective and provide new impetus for strategic development,” emphasizes Saori Dubourg, CEO of Greiner AG.
Bernhard Achleitner assumes role of CEO Greiner Mediscan effective January 1, 2026
With this reorganization of Greiner Mediscan, the company is sending a clear strategic signal for growth and expansion. Strengthening the existing team with a seasoned leader possessing comprehensive industry expertise underscores Greiner Mediscan's commitment to actively driving strategic development. “I look forward to working with the experienced Greiner Mediscan team to further drive international development and strategically deploy our innovative power to strengthen Greiner Mediscan’s position in a strongly growing market environment,” says Bernhard Achleitner, CEO of Greiner Mediscan.
Bernhard Achleitner brings over 18 years of experience in the pharmaceutical, generics, and biotechnology sectors. Most recently, he served as Head of Strategy and Operations at Novartis Austria, having previously held senior positions at Novartis Germany, EY, and Sandoz. He holds an Executive MBA in General Management, a Master’s degree in Business Informatics, and an engineering degree in Electrical Engineering. Markus Niederreiter, previously Managing Director of the subsidiary, will become part of the new Greiner Mediscan leadership team and will be responsible for technological development.
About Greiner Mediscan
Greiner Mediscan is one of Europe’s leading suppliers in the sterilization of medical products, the sterilization of food packaging and the functional improvement of plastics and semiconductors using ionizing radiation (E-beam, X-ray and Gamma technology). The company currently operates three sites in Kremsmünster and Seibersdorf. With a total of 70 employees, it generated revenue of approx. 20 million euros (2024), with about 70 percent of sales generated by third-party customers in the medical, food, automotive, and electronics industries.
